Greving JP, Diener HC, Reitsma JB, et al. Antiplatelet Therapy After Noncardioembolic Stroke. Stroke. 2019 Jul;50(7):1812-1818. doi: 10.1161/STROKEAHA.118.024497. Epub 2019 Jun 10. (Original study)

Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (=3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95% CI, 0.74-0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95% CI, 0.78-0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95% CI, 0.71-0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95% CI, 0.93-1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients =65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions- Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.

Discipline Area Score
Family Medicine (FM)/General Practice (GP) 6 / 7
General Internal Medicine-Primary Care(US) 6 / 7
Hemostasis and Thrombosis 6 / 7
Internal Medicine 6 / 7
Neurology 5 / 7
Comments from MORE raters

Family Medicine (FM)/General Practice (GP) rater

This study brings up again the discussion about the best antiplatelet for long-term secondary prevention after a CVA or TIA. Recent studies have provided some guidance of dual-antiplatelet therapy during the first month after an event, and just using aspirin long term. This study uses an NMA analysis to evaluate different treatments. This analysis postulates that clopidogrel and aspirin/dipyridamole are better long-term options. Clopidogrel has a better balance between benefits and risks. We will need to reconsider the role of long-term clopidogrel for these patients. I would like to see more studies replicating this data before making changes in the role of aspirin in secondary prevention.

Neurology rater

Since this network meta-analysis included patients more than 90 days after stroke, it excluded the high-risk early times after stroke. This study appears to be an example of immortal time bias. I prefer to use the results of the original RCTs in making my clinical judgements and I will not change my therapeutic approach based on this study.

Neurology rater

Number crunching for something we already know.

Neurology rater

This is a useful meta-analysis showing lower risks and higher benefits of clopidogrel or ASA/dipyridamole vs ASA alone in secondary prevention of ischemic stroke.
Comments from EvidenceAlerts subscribers

No subscriber has commented on this article yet.